Patents by Inventor Dawei Chen

Dawei Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Ether compounds for treatment of medical disorders
    Patent number: 10385097
    Abstract: Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an ether substituent (R32) are provided. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduce the excessive activation of complement.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: August 20, 2019
    Assignee: Achillion Pharmaceuticals, Inc.
    Inventors: Jason Allan Wiles, Avinash S. Phadke, Milind Deshpande, Atul Agarwal, Dawei Chen, Venkat Rao Gadhachanda, Akihiro Hashimoto, Godwin Pais, Qiuping Wang, Xiangzhu Wang
  • RAILWAY VEHICLE CARRIAGE STRUCTURE AND RAILWAY VEHICLE
    Publication number: 20190241200
    Abstract: Provided are a railway vehicle carriage structure and a railway vehicle. Doors (9) enabling passengers to board and alight are provided on two sides of a vehicle body of at least one end part of a carriage (1, 2), a region directly between the doors is a vestibule (12), and the space of the vestibule (12) is substantially circular. This type of carriage structure enlarges the passing space in the vestibule (12) for people, can effectively relieve the state of overcrowding when a large number of people are boarding and alighting, and increases the comfort of passengers of railway vehicles.
    Type: Application
    Filed: August 26, 2017
    Publication date: August 8, 2019
    Applicant: CRRC QINGDAO SIFANG CO., LTD.
    Inventors: Dawei CHEN, Huaxin HU, Qingjing DONG, Lan LIN
  • Carbamate, ester, and ketone compounds for treatment of complement mediated disorders
    Patent number: 10370394
    Abstract: Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof, wherein R12 or R13 on the A group is a carbamate, ester, or ketone substituent (R32) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: August 6, 2019
    Assignee: Achillion Pharmaceuticals, Inc.
    Inventors: Jason Allan Wiles, Venkat Rao Gadhachanda, Godwin Pais, Akihiro Hashimoto, Qiuping Wang, Dawei Chen, Xiangzhu Wang, Atul Agarwal, Milind Deshpande, Avinash S. Phadke
  • PHASE-CHANGE ENERGY STORAGE AIR DUCT AND AUTOMOBILE AIR CONDITIONING SYSTEM
    Publication number: 20190217680
    Abstract: A phase-change energy storage air duct of an automobile air conditioning system. A phase-change energy storage unit (2) is configured inside an air duct (1) of an air conditioning system. By means of phase-change heat absorption or release, residual heat in the air is absorbed, and the heat is released to air with a lower temperature, so that energy is recycled to achieve energy saving. The temperature of air entering a room or a carriage is kept stable, and thus the user experience is improved. When the air conditioning system fails, the phase-change energy storage unit (2) can still utilize stored cooling capacity or heat to cool down or heat up air in the air duct, so that a supply of air can be kept stable for a period of time, and thus the user experience is improved. The present application also relates to an automobile air conditioning system.
    Type: Application
    Filed: August 30, 2017
    Publication date: July 18, 2019
    Inventors: Shaoqing LIU, Jianying LIANG, Peng LIN, Dawei CHEN, Welbin WANG, Xiaoguang SUN, Chuanying LI, Yundong HAN, Shuanbao YAO, Jinyu ZHANG
  • ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS
    Publication number: 20190211033
    Abstract: Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an aryl, heteroaryl or heterocycle (R32) are provided. The inhibitors of Factor D described herein reduce the excessive activation of complement.
    Type: Application
    Filed: March 12, 2019
    Publication date: July 11, 2019
    Applicant: Achillion Pharmaceuticals, Inc.
    Inventors: Jason Allan Wiles, Avinash S. Phadke, Milind Deshpande, Atul Agarwal, Dawei Chen, Venkat Rao Gadhachanda, Akihiro Hashimoto, Godwin Pais, Qiuping Wang, Xiangzhu Wang
  • ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS
    Publication number: 20190185498
    Abstract: Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an aryl, heteroaryl or heterocycle (R32) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.
    Type: Application
    Filed: February 14, 2019
    Publication date: June 20, 2019
    Applicant: Achillion Pharmaceuticals, Inc.
    Inventors: Jason Allan Wiles, Venkat Rao Gadhachanda, Qiuping Wang, Godwin Pais, Akihiro Hashimoto, Dawei Chen, Xiangzhu Wang, Atul Agarwal, Milind Deshpande, Avinash S. Phadke
  • Phosphonate compounds for treatment of complement mediated disorders
    Patent number: 10301336
    Abstract: Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is a phosphonate (R32) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: May 28, 2019
    Assignee: Achillion Pharmaceuticals, Inc.
    Inventors: Jason Allan Wiles, Akihiro Hashimoto, Venkat Rao Gadhachanda, Godwin Pais, Qiuping Wang, Dawei Chen, Xiangzhu Wang, Atul Agarwal, Milind Deshpande, Avinash Phadke
  • PROCESS OF PRODUCING A LIQUID CRYSTAL DISPLAY AND A THERMOSET RESIN COMPOSITION USED IN THE SAME
    Publication number: 20190155077
    Abstract: The present invention relates to an improved one-drop-filling process of producing a liquid crystal display having a liquid crystal layer between a first substrate and a second substrate, comprising steps of applying a thermally curable resin composition on a sealing region at a periphery of a surface of the first substrate; conducting a first thermal curing of the thermally curable resin composition at a temperature of 40° C. to 75° C., and obtaining a partially cured product; dropping liquid crystal on a central area encircled by the sealing region of the surface of the first substrate or the corresponding area of the second substrate, and forming the liquid crystal layer; overlaying the second substrate on the first substrate; and conducting a second thermal curing of the partially cured product.
    Type: Application
    Filed: January 8, 2019
    Publication date: May 23, 2019
    Inventors: Baoshan Gao, Tengfang Wang, Minghai Wang, Kangcheng Lou, Dawei Chen
  • PROCESS OF PRODUCING A LIQUID CRYSTAL DISPLAY AND A CURABLE RESIN COMPOSITION USED IN THE SAME
    Publication number: 20190155078
    Abstract: The present invention relates to an improved one-drop-filling process of producing a liquid crystal display having a liquid crystal layer between a first substrate and a second substrate, comprising steps of applying a curable resin composition on a sealing region at a periphery of a surface of the first substrate; radiation curing the curable resin composition, and obtaining a partially cured product; dropping liquid crystal on a central area encircled by the sealing region of the surface of the first substrate or the corresponding area of the second substrate, and forming the liquid crystal layer; overlaying the second substrate on the first substrate; and thermal curing the partially cured product.
    Type: Application
    Filed: January 8, 2019
    Publication date: May 23, 2019
    Inventors: Qin LI, Jing LU, Minghai WANG, Dawei CHEN
  • AMINO COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS
    Publication number: 20190144473
    Abstract: Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof, wherein R12 or R13 on the A group is an amino substituent (R32) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.
    Type: Application
    Filed: January 14, 2019
    Publication date: May 16, 2019
    Applicant: Achillion Pharmaceuticals, Inc.
    Inventors: Venkat Rao Gadhachanda, Akihiro Hashimoto, Godwin Pais, Qiuping Wang, Dawei Chen, Xiangzhu Wang, Atul Agarwal, Milind Deshpande, Jason Allan Wiles, Avinash Phadke
  • Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders
    Patent number: 10287301
    Abstract: Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an aryl, heteroaryl or heterocycle (R32) are provided. The inhibitors of Factor D described herein reduce the excessive activation of complement.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: May 14, 2019
    Assignee: Achillion Pharmaceuticals, Inc.
    Inventors: Jason Allan Wiles, Avinash S. Phadke, Milind Deshpande, Atul Agarwal, Dawei Chen, Venkat Rao Gadhachanda, Akihiro Hashimoto, Godwin Pais, Qiuping Wang, Xiangzhu Wang
  • Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders
    Patent number: 10253053
    Abstract: Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an aryl, heteroaryl or heterocycle (R32) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: April 9, 2019
    Assignee: Achillion Pharmaceuticals, Inc.
    Inventors: Jason Allan Wiles, Venkat Rao Gadhachanda, Qiuping Wang, Godwin Pais, Akihiro Hashimoto, Dawei Chen, Xiangzhu Wang, Atul Agarwal, Milind Deshpande, Avinash S. Phadke
  • PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS
    Publication number: 20190085005
    Abstract: Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is a phosphonate (R32) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.
    Type: Application
    Filed: October 16, 2018
    Publication date: March 21, 2019
    Applicant: Achillion Pharmaceuticals, Inc.
    Inventors: Jason Allan Wiles, Akihiro Hashimoto, Venkat Rao Gadhachanda, Godwin Pais, Qiuping wang, Dawei Chen, Xiangzhu Wang, Atul Agarwal, Milind Deshpande, Avinash Phadke
  • ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS
    Publication number: 20190048033
    Abstract: Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an ether (R32) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.
    Type: Application
    Filed: October 18, 2018
    Publication date: February 14, 2019
    Applicant: Achillion Pharmaceuticals, Inc.
    Inventors: Jason Allan Wiles, Venkat Rao Gadhachanda, Godwin Pais, Akihiro Hashimoto, Qiuping Wang, Dawei Chen, Xiangzhu Wang, Atul Agarwal, Milind Deshpande, Avinash S. Phadke
  • COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS
    Publication number: 20190031692
    Abstract: Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.
    Type: Application
    Filed: October 1, 2018
    Publication date: January 31, 2019
    Applicant: Achillion Pharmaceuticals, Inc.
    Inventors: Jason Allan Wiles, Avinash S. Phadke, Xiangzhu Wang, Dawei Chen, Akihiro Hashimoto, Venkat Rao Gadhachanda, Godwin Pais, Qiuping Wang, Atul Agarwal, Milind Deshpande
  • Amino compounds for treatment of complement mediated disorders
    Patent number: 10189869
    Abstract: Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof, wherein R12 or R13 on the A group is an amino substituent (R32) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: January 29, 2019
    Assignee: Achillion Pharmaceuticals, Inc.
    Inventors: Venkat Rao Gadhachanda, Akihiro Hashimoto, Godwin Pais, Qiuping Wang, Dawei Chen, Xiangzhu Wang, Atul Agarwal, Milind Deshpande, Jason Allan Wiles, Avinash S. Phadke
  • ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS
    Publication number: 20190023729
    Abstract: Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an aryl, heteroaryl or heterocycle (R32) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.
    Type: Application
    Filed: September 24, 2018
    Publication date: January 24, 2019
    Applicant: Achillion Pharmaceuticals, Inc.
    Inventors: Jason Allan Wiles, Venkat Rao Gadhachanda, Qiuping Wang, Godwin Pais, Akihiro Hashimoto, Dawei Chen, Xiangzhu Wang, Atul Agarwal, Milind Deshpande, Avinash S. Phadke
  • Amide compounds for treatment of medical disorders
    Patent number: 10138225
    Abstract: Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an amide substituent (R32) are provided. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein are capable of reducing the excessive activation of complement.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: November 27, 2018
    Assignee: Achillion Pharmaceuticals, Inc.
    Inventors: Jason Allan Wiles, Avinash S. Phadke, Milind Deshpande, Atul Agarwal, Dawei Chen, Venkat Rao Gadhachanda, Akihiro Hashimoto, Godwin Pais, Qiuping Wang, Xiangzhu Wang
  • ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS
    Publication number: 20180305375
    Abstract: Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an aryl, heteroaryl or heterocycle (R32) are provided. The inhibitors of Factor D described herein reduce the excessive activation of complement.
    Type: Application
    Filed: June 15, 2018
    Publication date: October 25, 2018
    Applicant: Achillion Pharmaceuticals, Inc.
    Inventors: Jason Allan Wiles, Avinash S. Phadke, Milind Deshpande, Atul Agarwal, Dawei Chen, Venkat Rao Gadhachanda, Akihiro Hashimoto, Godwin Pais, Qiuping Wang, Xiangzhu Wang
  • SUBSITUTED ALIPHANES, CYCLOPHANES, HETERAPHANES, HETEROPHANES, HETERO-HETERAPHANES AND METALLOCENES USEFUL FOR TREATING HCV INFECTIONS
    Publication number: 20180303800
    Abstract: The present disclosure provides substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes, of Formula I D-M-D??(Formula I) useful as antiviral agents. In certain embodiments disclosed herein M is a group —P-A-P— where A is Certain substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. Pharmaceutical compositions/and combinations containing one or more substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes and a pharmaceutically acceptable carrier are also provided by this disclosure. Methods for treating viral infections, including Hepatitis C viral infections are provided by the disclosure.
    Type: Application
    Filed: June 29, 2018
    Publication date: October 25, 2018
    Inventors: Jason Allan Wiles, Qiuping Wang, Akihiro Hashimoto, Godwin Pais, Xiangzhu Wang, Venkat Gadhachanda, Avinash Phadke, Milind Deshpande, Dawei Chen